MediWound Ltd
The objectives of this study are: * To evaluate the safety of EscharEx and its placebo Gel Vehicle compared to non-surgical standard of care (NSSOC) * To assess the efficacy of EscharEx (EX-03 5% formulation) compared to placebo control and compared to NSSOC.
45 eligible adult participants with VLU (with a surface area between 2 cm2 and 40 cm2 , and wound age between 4 weeks and 18 months), will be randomized. The participants will be treated with IMP (either EX-03 5% or placebo) in a double blinded manner or with NSSOC in unblinded manner. Total duration of the study is up to 17 weeks: Screening period (2 visits, 7 days apart), Daily Visits Period (debridement with IMP/NSSOC): up to 8 daily site visits, (or less if a complete debridement occurred before 8 visits) within 14 days. Weekly Visits Period (Wound management): the weekly period will i…
Inclusion Criteria: Criteria: Inclusion Criteria 1. Men or women, older than 18 years of age, 2. Participants with VLU (determined by medical history, physical examination, and a documented ultrasound scan demonstrating venous insufficiency), 3. Wound is present for at least 4 weeks but no longer than 18 months 4. The adherent necrotic/thick slough/fibrin non-viable tissue area, assessed following wound cleansing with wet gauze and sterile saline or water and mild soap, is at least 50% of the wound area (assessed by clinical evaluation), 5. Target wound surface area is in the range of 2-40…
a sterile lyophilized powder containing a concentrate of proteolytic enzymes enriched in bromelain (anacaulase-bcdb). The powder and sterile water are mixed to form a gel prior to application on the wound area.
A sterile powder containing excipients only (no proteolytic enzymes). The powder and sterile water are mixed to form a gel prior to application on the wound area
Various dressings and Collagenase
Arctuva estimate
Actual pay is set by the research site.
Verify or correct the compensation shown for this listing.